市場調査レポート

商品コード

1633544

ぶどう膜炎治療薬の市場規模、シェア、成長分析：疾患タイプ別、治療タイプ別、原因別、投与経路別、流通チャネル別、適応症別、地域別 - 産業予測 2025～2032年

Uveitis Treatment Market Size, Share, Growth Analysis, By Disease Type, By Treatment Type, By Cause, By Route of Administration, By Distribution Channel, By Indication, By Region - Industry Forecast 2025-2032

出版日: 2025年01月12日
発行: SkyQuest
ページ情報: 英文 239 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 3,500 504,210円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 4,400 633,864円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 5,300 763,518円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
目次

概要

サンプル依頼リストに入れる

ぶどう膜炎治療薬の世界市場規模は、2023年に7億5,800万米ドルと評価され、2024年の8億879万米ドルから2032年には13億5,878万米ドルに成長し、予測期間（2025～2032年）のCAGRは6.7%で成長する見通しです。

眼科市場は、研究開発活動の活発化によって力強い拡大が見られます。眼の炎症、特に難治性の後部ぶどう膜炎や中間ぶどう膜炎を対象とした臨床試験が世界的に増加しています。現在の第III相試験では、ミコフェノール酸モフェチルやメトトレキサートなどの革新的な治療法が評価されており、これらは非感染性ぶどう膜炎に対する標準的なコルチコステロイド治療に代わるものとして位置づけられています。さらに、広範な研究開発努力による生物学的薬剤の開発が進み、眼の炎症性疾患に対する治療法が充実してきました。この進化は治療の選択肢を多様化させるだけでなく、こうした革新的な治療に対する需要の高まりにも拍車をかけており、眼科領域における市場全体の成長を後押ししています。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
市場の最近の動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 会社概要
- 製品ポートフォリオ分析
- セグメント別シェア分析
- 収益の前年比比較（2022～2024年）

主要企業プロファイル

AbbVie Inc.（United States）
Novartis AG（Switzerland）
Bausch Health Companies Inc.（Canada）
EyePoint Pharmaceuticals, Inc.（United States）
Santen Pharmaceutical Co., Ltd.（Japan）
Alimera Sciences, Inc.（United States）
Clearside Biomedical, Inc.（United States）
Eyegate Pharmaceuticals, Inc.（United States）
Horizon Therapeutics Plc（Ireland）
Mylan N.V.（United States）
Sun Pharmaceutical Industries Ltd.（India）
Regeneron Pharmaceuticals, Inc.（United States）
Merck & Co., Inc.（United States）
Otsuka Pharmaceutical Co., Ltd.（Japan）
Pfizer Inc.（United States）
Amgen Inc.（United States）
Sanofi（France）
Galapagos NV（Belgium）
Tarsier Pharma Ltd.（Israel）
TopiVert Ltd.（United Kingdom）

結論と推奨事項

Product Code: SQMIG35A2404

Global Uveitis Treatment Market size was valued at USD 758.0 million in 2023 and is poised to grow from USD 808.79 million in 2024 to USD 1358.78 million by 2032, growing at a CAGR of 6.7% during the forecast period (2025-2032).

The ophthalmology market is witnessing a robust expansion fueled by intensified research and development activities. A growing number of clinical trials are underway globally, targeting eye inflammation issues, particularly refractory posterior and intermediate uveitis. Current phase III trials are assessing innovative therapies like mycophenolate mofetil and methotrexate, which are being positioned as alternatives to standard corticosteroid treatments for noninfectious uveitis. Moreover, advancements in the development of biological drugs through extensive R&D efforts have enriched the therapeutic landscape for eye inflammation disorders. This evolution is not only diversifying treatment options but also spurring heightened demand for these innovative therapies, thereby propelling overall market growth in the field of ophthalmology.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Uveitis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Uveitis Treatment Market Segmental Analysis

Global Uveitis Treatment Market is segmented by Disease Type, Treatment Type, Cause, Route of Administration, Distribution Channel, Indication and region. Based on Disease Type, the market is segmented into Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis and Panuveitis. Based on Treatment Type, the market is segmented into Corticosteroids, Immunosuppressant, Monoclonal Antibodies, Cycloplegic Agents, Antibiotics, Antivirals, Antifungal and Analgesics. Based on Cause, the market is segmented into Infectious and Non-infectious. Based on Route of Administration, the market is segmented into Topical, Systemic, Injectable and Intravitreal. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on Indication, the market is segmented into Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis and Panuveitis. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Uveitis Treatment Market

The global uveitis treatment market is primarily driven by the rising incidence and prevalence of uveitis across the globe, fueled by factors such as autoimmune diseases, infections, and inflammatory conditions. The introduction of innovative treatment options, including biologic therapies, immunosuppressants, and targeted therapies, has greatly enhanced the management of this condition, leading to more effective and specific treatment modalities. Additionally, heightened awareness surrounding uveitis among healthcare professionals and patients has facilitated earlier diagnoses and prompt treatment, further increasing the demand for various uveitis treatment options. These elements collectively contribute to the robust growth of the uveitis treatment market.

Restraints in the Global Uveitis Treatment Market

Global Uveitis Treatment faces significant challenges including limited access to healthcare facilities and specialized care in low-resource settings, contributing to disparities in diagnosis and management across regions. The diversity in underlying causes of uveitis, ranging from infectious to autoimmune and idiopathic origins, complicates standardized treatment protocols. Additionally, varying levels of awareness and education among healthcare providers can lead to mismanagement or delayed treatment. Economic constraints, coupled with the availability of medications, further restrict effective treatment options. Therefore, addressing these barriers necessitates a coordinated global effort to improve access to education, resources, and healthcare infrastructure for uveitis management globally.

Market Trends of the Global Uveitis Treatment Market

The Global Uveitis Treatment market is witnessing significant trends driven by innovation and personalized medicine. There is an accelerated development of targeted therapies, particularly biologics and immunomodulatory drugs, enhancing the management of inflammation in uveitis patients. The adoption of sustained-release drug delivery systems, such as intravitreal implants, is growing, facilitating prolonged drug action and minimizing injection frequency. Furthermore, personalized medicine is gaining traction as genetic and molecular profiling offers tailored treatment strategies. Collaborations between pharmaceutical firms and research institutions are fostering the creation of novel therapies, while the infusion of advanced technologies like AI and telemedicine is revolutionizing patient monitoring and management.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technological Advancement

Global Uveitis Treatment Market Size by Disease Type & CAGR (2025-2032)

Market Overview
Anterior Uveitis
Posterior Uveitis
Intermediate Uveitis
Panuveitis

Global Uveitis Treatment Market Size by Treatment Type & CAGR (2025-2032)

Market Overview
Corticosteroids
Immunosuppressant
Monoclonal Antibodies
Cycloplegic Agents
Antibiotics
Antivirals
Antifungal
Analgesics

Global Uveitis Treatment Market Size by Cause & CAGR (2025-2032)

Market Overview
Infectious
Non-infectious

Global Uveitis Treatment Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Topical
Systemic
Injectable
Intravitreal

Global Uveitis Treatment Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Global Uveitis Treatment Market Size by Indication & CAGR (2025-2032)

Market Overview
Anterior Uveitis
Intermediate Uveitis
Posterior Uveitis
Panuveitis

Global Uveitis Treatment Market Size & CAGR (2025-2032)

North America (Disease Type, Treatment Type, Cause, Route of Administration, Distribution Channel, Indication)
- US
- Canada
Europe (Disease Type, Treatment Type, Cause, Route of Administration, Distribution Channel, Indication)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Disease Type, Treatment Type, Cause, Route of Administration, Distribution Channel, Indication)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Disease Type, Treatment Type, Cause, Route of Administration, Distribution Channel, Indication)
- Brazil
- Rest of Latin America
Middle East & Africa (Disease Type, Treatment Type, Cause, Route of Administration, Distribution Channel, Indication)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

AbbVie Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
EyePoint Pharmaceuticals, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Santen Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alimera Sciences, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Clearside Biomedical, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eyegate Pharmaceuticals, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Horizon Therapeutics Plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Galapagos NV (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tarsier Pharma Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TopiVert Ltd. (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

ぶどう膜炎治療薬の市場規模、シェア、成長分析：疾患タイプ別、治療タイプ別、原因別、投与経路別、流通チャネル別、適応症別、地域別 - 産業予測 2025～2032年

Uveitis Treatment Market Size, Share, Growth Analysis, By Disease Type, By Treatment Type, By Cause, By Route of Administration, By Distribution Channel, By Indication, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

ぶどう膜炎治療薬市場規模：疾患タイプ別

ぶどう膜炎治療薬市場規模：治療タイプ別

ぶどう膜炎治療薬市場規模：原因別

ぶどう膜炎治療薬市場規模：投与経路別

ぶどう膜炎治療薬市場規模：流通チャネル別

ぶどう膜炎治療薬市場規模：適応症別

ぶどう膜炎治療薬市場規模